- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.
- -
-
Page/Page column 18; 19
(2021/04/17)
-
- N-SUBSTUTUTED-6-OXO-1,6-DIHYDROPYRIMIDINE-2-YL DERIVATIVES AS INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula I
- -
-
Page/Page column 22
(2021/04/10)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
A compound of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: (I)
- -
-
Page/Page column 12-13
(2021/09/11)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: (I)
- -
-
Page/Page column 19-20
(2021/09/11)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
A pharmaceutical composition comprising the compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id, or a pharmaceutically acceptable salt thereof, is set forth. (Formula Ia), (Formula Ib), (Formula Ic), (Formula Id)
- -
-
Page/Page column 17-18
(2021/10/22)
-
- N-SUBSTITUTED-4-OXO-3,4-DIHYDROPYRIDO[2,3-D]PYRIMIDIN-2-YL DERIVATIVES AS INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth Formula I.
- -
-
Page/Page column 30-31
(2021/04/10)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula I.
- -
-
Page/Page column 24-25
(2021/04/10)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula I
- -
-
Page/Page column 32-33
(2020/04/25)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula I
- -
-
Page/Page column 28-29
(2020/05/07)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds of Formula (I), including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
- -
-
Page/Page column 127
(2020/06/10)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds of Formula I, and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula (I).
- -
-
Page/Page column 55; 56
(2020/06/01)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds of Formula (I), including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.
- -
-
Page/Page column 75; 76
(2020/06/10)
-
- QUINAZOLINYL-INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula (I):
- -
-
Page/Page column 67-68
(2020/05/28)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds of Formula (I), including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.
- -
-
Page/Page column 88-89
(2020/05/29)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
The compound (I) and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.
- -
-
Page/Page column 18
(2020/08/22)
-
- PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
The compound and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
- -
-
Page/Page column 18-19
(2021/01/22)
-
- INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
-
Compounds and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.
- -
-
Page/Page column 121-122
(2020/06/01)
-
- A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 1. Construction of the basic framework
-
A novel class of potent, selective, and orally active non-peptide bradykinin (BK) B2 receptor antagonists were designed and synthesized starting from 8-benzyloxyimidazo[1,2-α]pyridine derivative 2. The unique screening lead (2) was discovered b
- Abe, Yoshito,Kayakiri, Hiroshi,Satoh, Shigeki,Inoue, Takayuki,Sawada, Yuki,Imai, Keisuke,Inamura, Noriaki,Asano, Masayuki,Hatori, Chie,Katayama, Akira,Oku, Teruo,Tanaka, Hirokazu
-
p. 564 - 578
(2007/10/03)
-
- CATALYTIC ACTIVITY AND CHEMICAL STABILITY OF PERHALOGENATED Mn(III)-TETRAARYLPORPHYRINS IN ALKENE EPOXIDATIONS
-
Structural factors, which govern the chemical stability of metallo-tetraaryl porphyrins, were investigated in CH2Cl2/H2O two-phase alkene epoxidations promoted by aqueous NaOCl or 30percent H2O2. In contrast to recent literature reports, the perhalogenati
- Banfi, Stefano,Mandelli, Roberta,Montanari, Fernando,Quici, Silvio
-
p. 409 - 415
(2007/10/02)
-
